索拉非尼靶向治疗晚期肾癌的临床价值分析

Clinical analysis of sorafenib targeted treatment for advanced kidney cancer

目的探讨索拉非尼治疗晚期肾癌的临床应用价值。方法将2010年1月至2012年12月我院诊治的76例晚期肾癌患者随机分成2组:对照组38例,采用IFN-α、IL-2交替治疗;实验组38例,采用索拉非尼治疗。观察比较两组的近期疗效、毒副作用及生活质量评分。结果实验组的总控制率显著性高于对照组(P<0.05);实验组的主要不良反应为手足皮肤反应、皮疹/脱皮等;实验组的发热、恶心等不良反应发生率显著低于对照组(P<0.05);实验组治疗后的躯体功能、角色功能、情感功能评分均显著高于对照组(P<0.05)。结论索拉非尼治疗晚期肾癌能更好地控制癌变,减少毒副作用,提高患者的生活质量。

Objective To investigate the clinical value of sorafenib targeted treatment for advanced kidney cancer. Methods 76 cases of advanced kidney cancer patients admitted to our hospital from January 2010 to December 2012 were randomly divided into two groups, control group （n = 38 ）and treatment group （n = 38 ）. Control group was given IFN-α and IL-2, and treatment group was given sorafenib. The clinical efficacy, incidence of adverse reactions and quality of life score in the two groups were observed and compared. Results The total cancer control rate in treatment group was significantly higher than that in control group （P 〈 0. 05 ） ; the major adverse events were hand-foot skin reaction, rash/desquamation in treatment group, and the incidence of fever and nausea in treatment group were significantly lower than those in the control group（ P 〈 0.05 ） ;the scores of physical function ,role function and emotional function in treatment group after treatment were significantly higher than those in control group （ P 〈 0. 05 ）. Conclusion The clinical application of sorafenib targeted treatment for advanced kidney cancer can significantly control the development of cancer, reduce adverse reactions and improve the patient＇s quality of life.